Press Release

Aduro BioTech’s Chief Scientific Officer, Thomas W. Dubensky, Jr., Ph.D., a featured speaker on action of vaccine adjuvants at Keystone SymposiaOctober 09, 2014 4:47 p.m. ET

October 09, 2014 08:00 AM Eastern Daylight Time

BERKELEY, Calif. -- Aduro BioTech, Inc., a leader in the development of therapies for immuno-oncology, announced today that Thomas W. Dubensky, Jr., Ph.D., chief scientific officer at the company, was a featured speaker at the Keystone Symposia conference on “The Modes of Action of Vaccine Adjuvants” being held in Seattle, WA this week where he presented preclinical data on the company’s cyclic-di-nucleotide (CDN) technology. The company is using CDNs to develop potent therapies that activate and enhance innate immunity, the body’s first line of defense against pathogens, which is emerging as an important mechanism in immuno-oncology applications.

In his presentation, Dr. Dubensky provided an overview of the company’s approach for targeting the STING (stimulator of interferon genes) pathway with particular synthetic derivatives of CDNs that resulted in eradication of treated tumors and induction of systemic tumor-specific immunity in several aggressive preclinical tumor models. These findings serve as the rationale for advancement to evaluation of these molecules in patients with cancer.

“These are particularly encouraging data, which provide evidence that our proprietary CDN derivatives are significantly more potent than natural stimulators of STING,” said Dr. Dubensky. “We look forward to advancing our CDN technology into Phase 1 clinical trials next year to further evaluate its potential in tumors that are resistant to standard of care. In addition, we will continue to explore the broad potential and versatility of CDNs in the development of therapeutic and preventative vaccines.”

About Aduro BioTech, Inc.

Aduro BioTech, Inc. is a private, clinical-stage biotechnology company focused on immunotherapy for cancer. Aduro has received Breakthrough Therapy Designation from the FDA for its novel immunotherapy combination in pancreatic cancer which is in an ongoing Phase 2B clinical trial, ECLIPSE, and has additional ongoing clinical trials with its LADD platform in mesothelioma and glioblastoma. The company is also developing clinical candidates using novel small molecules that activate the intracellular STING receptor, a central mediator of the innate immune response. For more information, please visit www.adurobiotech.com.

Contacts

Aduro BioTech, Inc.
Greg W. Schafer, 510-809-4801
Chief Operating Officer
or
Media Contact:
Angela Bitting, 925-202-6211
a.bitting@comcast.net